Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis (Q45739392)

15 December 2017

title

Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis (English)

1 reference

15 December 2017

Lofland JH

1

1 reference

15 December 2017

O'Connor JP

2

1 reference

15 December 2017

Chatterton ML

3

1 reference

15 December 2017

Moxey ED

4

1 reference

15 December 2017

Paddock LE

5

1 reference

15 December 2017

Nash DB

6

1 reference

15 December 2017

Desai SA

7

1 reference

15 December 2017

publication date

1 November 2000

1 reference

15 December 2017

published in

Clinical Therapeutics

1 reference

15 December 2017

volume

22

1 reference

15 December 2017

issue

11

1 reference

15 December 2017

page(s)

1357-1369

1 reference

Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection

15 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983032-5

7 January 2021

National surveillance for respiratory syncytial virus, United States, 1985-1990.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983032-5

7 January 2021

Epidemiology of acute lower respiratory disease in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983032-5

7 January 2021

Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983032-5

7 January 2021

Birth weight and hospital readmission of infants born prematurely

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983032-5

7 January 2021

Rehospitalization of the very-low-birth-weight infant. A continuum of perinatal and environmental morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983032-5

7 January 2021

Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983032-5

7 January 2021

Comments on palivizumab (Synagis)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983032-5

7 January 2021

Questions about palivizumab (Synagis)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983032-5

7 January 2021

Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983032-5

7 January 2021

Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983032-5

7 January 2021

Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983032-5

7 January 2021

Rapid changes for academic medical centers. 1

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983032-5

7 January 2021

Mother and father interactions over the first year with term and preterm infants

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983032-5

7 January 2021

Effect of neonatal complications in premature infants on early parent-infant interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983032-5

7 January 2021

10.1016/S0149-2918(00)83032-5

Identifiers

DOI

1 reference

15 December 2017

1 reference